ClinicalTrials.gg
RecruitingNCT07606807SIMPLIFIEDUpdated Jun 15, 2026

rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window

A Phase 3 interventional study of Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) and Standard medical treatment in Acute Ischemic Stroke, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
19th of 59
750 · median 466
Started
2026
with 10 others
Phase 3
37 of 59
23 open now
Primary completion
2028-12
later than 22 of 31 live
Registered
54th of 59
by date
Lead sponsor
2 of 59
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 19th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 22 of the 31 other live ones, and was the 54th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour window, using a simplified imaging selection strategy based solely on non-contrast CT (NCCT).

Read the detailed description

The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study with a target enrollment of at least 750 patients. The trial focuses on individuals with acute ischemic stroke (AIS) presenting within a 4.5 to 24-hour window who are not planned for endovascular thrombectomy (EVT). Patients meeting simplified imaging criteria based on non-contrast CT (NCCT) are randomized 1:1 to receive a single intravenous bolus of 0.25 mg/kg tenecteplase (TNK) or standard medical treatment. The primary outcome is the 90-day excellent functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1. Safety outcomes include symptomatic intracranial hemorrhage (sICH) and 90-day mortality.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Intravenous Thrombolysis
  • Extended Time Window
  • Simplified Imaging
  • Non-contrast CT
  • Tenecteplase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Presumed acute ischemic stroke of the anterior circulation.
  3. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrollment; including wake-up stroke and unwitnessed stroke, onset time refers to 'last-known well time'.
  4. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive).
  5. Limited early ischemic changes on non-contrast CT (NCCT).
  6. Written signed by patients or their legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  1. Clearly demarcated hypodensity on non-contrast CT related to the current stroke, with limited anticipated clinical benefit as judged by the investigator.
  2. Intracranial or subarachnoid hemorrhage identified on baseline NCCT.
  3. Endovascular thrombectomy (EVT) planned at the time of randomization.
  4. Pre-stroke mRS≥2.
  5. Allergy to the test drug and its ingredients.
  6. Severe head trauma or ischemic stroke in the last 3 months.
  7. Intracranial or intraspinal surgery within 3 months before enrollment.
  8. Intracranial tumor or large-size aneurysm found before enrollment.
  9. Gastrointestinal or urinary system hemorrhage within the past 3 weeks.
  10. Active visceral bleeding.
  11. Aortic arch dissection confirmed by examination or medical history.
  12. Infective endocarditis confirmed by examination or medical history.
  13. count less than 100 × 109 /L.
  14. Patients received heparin or low-molecular-weighted heparin treatment within 24h before enrollment.
  15. Pregnant or lactating women.
  16. Blood glucose \<50 mg/dl (2.78mmol/L) or >400 mg/dl (22.2mmol/L) during screening.
  17. Uncontrolled hypertension with persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, to medical management.
  18. less than 6 months due to , severe cardiopulmonary disease, or other terminal illness.
  19. Participating in other trials.
  20. Other conditions deemed unsuitable for the study by the investigator, such as inability to comprehend or comply with study procedures or follow-up due to mental illness, cognitive or emotional disorder.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Intravenous tenecteplase

    Drug: Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)

  • Active comparator
    Control Arm

    Standard medical treatment

    Drug: Standard medical treatment

Interventions

  • DrugTenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)

    Drug page: TenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to the intervention arm will receive tenecteplase via a single intravenous bolus (0.25 mg/kg; maximum dose 25 mg), administered immediately following randomization.

  • DrugStandard medical treatment

    Patients in the control arm will receive standard medical treatment.

06

What researchers measure

Primary outcomes

  1. Excellent functional outcome

    The proportion of mRS score 0-1 at 90 (±14) days.

    Time frame: at 90 (±14) days

Secondary outcomes

  1. Ordinal distribution of mRS

    The proportion of mRS distribution at 90 (±14) days

    Time frame: at 90 (±14) days

  2. Favorable functional outcome

    The proportion of mRS score 0-2 at 90 (±14) days

    Time frame: at 90 (±14) days

  3. Change in NIHSS Score at 24 (±12) hours

    NIHSS score change from baseline at 24 (±12) hours

    Time frame: at 24 (±12) hours

  4. Change in NIHSS Score at 7 (±1) days or discharge

    NIHSS score change from baseline at 7 (±1) days or discharge

    Time frame: at 7 (±1) days or discharge

  5. Quality of life (EQ-5D-5L)

    Quality of life measured by EQ-5D-5L at 90 (±14) days

    Time frame: at 90 (±14) days

  6. Symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage (sICH) within 36 hours from randomization (SITS-MOST criteria)

    Time frame: within 36 hours

  7. Any intracranial hemorrhage

    Any intracranial hemorrhage within 36 hours

    Time frame: within 36 hours

  8. Major extracranial bleeding

    Major extracranial bleeding within 36 hours (GUSTO criteria: moderate and severe bleeding)

    Time frame: within 36 hours

  9. Mortality

    All-cause mortality within 90 days

    Time frame: within 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The IPD will be available from the Principal Investigator upon reasonable request 6 months after the trial completion.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 months after the trial completion.

Access criteria: The IPD will be available from the Principal Investigator upon reasonable request 6 months after the trial completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 28 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 26, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606807
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Jinyuan Wang
Contact
wangjy257@mail2.sysu.edu.cn
86-18558992193
Xinguang Yang, MD, PhD
Contact
yangxinguang0926@163.com
Yamei Tang, MD, PhD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion